News & Publications
Recent Press Releases
Cyteir Therapeutics Advances Clinical Trial of Lead RAD51 Synthetic Lethality Program in Cancer and Expands Senior Leadership Team
Cyteir Therapeutics Advances Clinical Trial of Lead RAD51 Synthetic Lethality Program in Cancer [...]
Cyteir Therapeutics Secures Additional $40.2 Million in its Series B Financing and Doses First Patient in Phase 1/2 Study of First-in-Class RAD51 Inhibitor
Cyteir Therapeutics Secures Additional $40.2 Million in its Series B Financing and Doses [...]
Cyteir Therapeutics Announces New Data Demonstrating Lead Compound CYT-0851 is Active Against Lymphomas and Solid Tumors, Synergistic with PARP Inhibitors
Cyteir Therapeutics Announces New Data Demonstrating Lead Compound CYT-0851 is Active Against Lymphomas [...]
Cyteir Therapeutics Secures $29 Million Series B to Advance Novel, Molecularly Targeted Therapies for Cancer and Autoimmune Diseases
Cyteir Therapeutics Secures $29 Million Series B to Advance Novel, Molecularly Targeted Therapies [...]
Recent Cyteir Publications
AACR 2019
Day M, Maclay T, Mills K. A novel RAD51 inhibitor, CYT01B, shows anti-cancer activity in preclinical models of AID expressing solid tumors.
Publications
- Ratiu JJ, Racine JJ, Hasham MG, Wang, Q, Branca J, Chapman HD, Zhu J, Donghia N, Philip V, Schott WH, Wasserfall C, Atkinson MA, Mills KD, Leeth CM, Serreze DV. Genetic and Small Molecule Disruption of the AID/RAD51 Axis Similarly Ptotects Nonobese Diabetic Mice from Type 1 Diabetes through Expansion of Regulatory B Lymphocytes. (2017) Journal of Immunology. June; 198(11): 4255-4267. Doi: 10.4049/jimmunol.1700024. Epub 2017 May 1. PMID: 28461573
Lamont KR, Hasham MG, Donghia NM, Branca J, Chavaree M, Chase B, Breggia A, Hedlund J, Emery I, Cavallo F, Jasin M, Ruter J, Mills KD. Attenuating homologous recombination stimulate an AID-induced antileukemic effect. (2013) Journal of Experimental Medicine. May; 210(5):1021-33.
Hasham MG, Donghia NM, Coffey E, Maynard J, Snow KJ, Ames J, Wilpan RY, He Y, King BL, Mills KD. Widespread genomic breaks generated by activation-induced cytidine deaminase are prevented by homologous recombination. (2010) Nature Immunology. September; 11(9): 820-826.